Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676376 | 0.88 | CYP2D6 (0.31) | CYP2D6 | |
| SCHEMBL24327757 | 0.88 | CYP2D6 (0.31) | CYP2D6ALDH1A1 | |
| SCHEMBL21733072 | 0.87 | — | — | |
| SCHEMBL22306122 | 0.86 | CYP2D6 (0.41) | CYP2D6ALDH1A1 | |
| SCHEMBL22007055 | 0.85 | — | — | |
| SCHEMBL19852105 | 0.85 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19852444 | 0.85 | — | — | |
| SCHEMBL21159020 | 0.85 | OPRM1 (0.35) | — | |
| SCHEMBL19346292 | 0.83 | — | — | |
| SCHEMBL25893729 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4219479-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2022063197-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | 上海美悦生物科技发展有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022063333-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | 上海美悦生物科技发展有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10329280-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885ALDH1A1 2904/4885SLC6A2 4431/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | CYP2D6 3454/4885ALDH1A1 1432/4885SLC6A2 4308/4885 |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | CYP2D6 3557/4885ALDH1A1 1517/4885SLC6A2 4335/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | CYP2D6 3589/4885ALDH1A1 4172/4885SLC6A2 4827/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885ALDH1A1 1432/4885SLC6A2 4308/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885ALDH1A1 4414/4885SLC6A2 1493/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | CYP2D6 3589/4885ALDH1A1 4172/4885SLC6A2 4827/4885 |
| US-10329280-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885ALDH1A1 1432/4885SLC6A2 4308/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885ALDH1A1 4414/4885SLC6A2 1493/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | CYP2D6 3454/4885ALDH1A1 1432/4885SLC6A2 4308/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | CYP2D6 3714/4885ALDH1A1 1477/4885SLC6A2 4096/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | CYP2D6 2931/4885ALDH1A1 4414/4885SLC6A2 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.